Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Net Income (2022 - 2025)

Historic Net Income for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' Net Income rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11754.08%. This contributed to the annual value of -$85.4 million for FY2024, which is 6909.89% up from last year.
  • As of Q3 2025, Atara Biotherapeutics' Net Income stood at -$4.3 million, which was up 8035.97% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Atara Biotherapeutics' Net Income peaked at $38.0 million during Q1 2025, and registered a low of -$88.1 million during Q1 2022.
  • Over the past 4 years, Atara Biotherapeutics' median Net Income value was -$31.8 million (recorded in 2024), while the average stood at -$36.9 million.
  • Per our database at Business Quant, Atara Biotherapeutics' Net Income plummeted by 48507.53% in 2023 and then skyrocketed by 21970.9% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Net Income stood at -$74.7 million in 2022, then grew by 18.72% to -$60.7 million in 2023, then skyrocketed by 79.09% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
  • Its Net Income was -$4.3 million in Q3 2025, compared to $2.4 million in Q2 2025 and $38.0 million in Q1 2025.